# Dyslipidemia

Manage dyslipidemia by separating LDL-C–driven ASCVD risk from triglyceride-driven pancreatitis risk, excluding secondary causes, identifying familial disease, and escalating from maximally tolerated statins to evidence-based nonstatins according to residual risk and lipid response.

**Clinical question:** How should clinicians evaluate dyslipidemia and select lipid-lowering therapy for ASCVD prevention and severe hypertriglyceridemia?

Updated: 2026-09-16T00:16:20.115770+00:00

## What matters in practice
- Use a maximally tolerated statin as the pharmacologic foundation for ASCVD secondary prevention; greater LDL-C lowering is associated with greater ASCVD risk reduction. [2]
- Measure lipoprotein(a) at least once in adulthood; values at or above 125 nmol/L (50 mg/dL) are risk-enhancing and should prompt more intensive LDL-C lowering and control of other risk factors. [3][4]
- When triglycerides are persistently 500 to 999 mg/dL, prioritize a low-fat diet and consider fenofibrate or prescription omega-3 fatty acids to reduce pancreatitis risk; add or intensify statin therapy in patients aged 40 to 75 years with ASCVD, diabetes, or at least 5% 10-year risk. [14]
- In persistent LDL-C elevation despite maximally tolerated statin therapy, add ezetimibe first for most patients; use a PCSK9 monoclonal antibody earlier when a reduction greater than 25% is needed or risk is very high. [11][12]
- Exclude secondary dyslipidemia before diagnosing familial hypercholesterolemia, then apply Dutch Lipid Clinic Network, Simon Broome, or ACC/AHA criteria when the phenotype suggests inherited LDL receptor disease. [11]

## Classify the lipid abnormality by the decision it changes

Separate ASCVD-risk management from urgent pancreatitis-risk reduction before choosing a drug.

For LDL-C–predominant dyslipidemia, establish whether the patient has clinical ASCVD, diabetes, severe primary hypercholesterolemia, or a primary-prevention risk decision. Statins remain the treatment foundation for secondary prevention because of established efficacy, safety, tolerability, and cost-effectiveness; ASCVD risk reduction rises in graded fashion with the magnitude of LDL-C lowering. [2]

Do not interpret an isolated LDL-C value as the complete atherogenic burden when triglycerides are elevated, diabetes is present, or achieved LDL-C is below 70 mg/dL. Order apolipoprotein B in these settings when residual particle-related risk could be underestimated by the standard lipid panel; non-HDL-C is also readily calculated without added cost and reflects all atherogenic cholesterol. [3][5][15]

Separate severe hypertriglyceridemia from LDL-C treatment escalation. Persistent fasting triglycerides of 500 to 999 mg/dL warrant a pancreatitis-prevention strategy centered on a low-fat diet and consideration of fenofibrate or prescription omega-3 fatty acids. In adults aged 40 to 75 years with ASCVD, diabetes, or 10-year ASCVD risk of at least 5%, simultaneously initiate or intensify statin therapy. [14]
- Order ApoB when triglycerides are at least 150 mg/dL, diabetes is present, or achieved LDL-C is below 70 mg/dL and residual atherogenic particle burden may alter treatment intensity. [3]
- Calculate non-HDL-C from the routine lipid panel when triglycerides are elevated or LDL-C may be less reliable in obesity, metabolic syndrome, or type 2 diabetes. [15]
- Use fasting triglycerides to direct pancreatitis-risk management when values are 500 mg/dL or higher. [14]

*Lipid patterns that change the immediate management objective. [3][11][14][15]*

| Predominant finding | Interpretation | Immediate next action |
| --- | --- | --- |
| LDL-C remains elevated on statin therapy | Residual LDL-C–mediated ASCVD risk; expected LDL-C reduction needed determines nonstatin choice. [11][12] | Confirm maximally tolerated statin use; add ezetimibe for most patients or consider earlier PCSK9 inhibition if more than 25% further LDL-C lowering is required. [11][12] |
| Fasting TG 500-999 mg/dL | Pancreatitis-risk range requiring triglyceride-directed intervention. [14] | Institute a low-fat diet; consider fenofibrate or prescription omega-3 fatty acids, and intensify statin therapy when ASCVD risk indications are present. [14] |
| Elevated TG, diabetes, or LDL-C <70 mg/dL | LDL-C can underestimate atherogenic particle burden. [3][15] | Measure ApoB and use non-HDL-C to refine residual risk assessment. [3][15] |
| Very high untreated LDL-C phenotype after secondary causes excluded | Consider heterozygous or homozygous familial hypercholesterolemia. [11] | Apply formal familial hypercholesterolemia criteria and determine whether advanced therapy is needed. [11][12] |

## Exclude secondary dyslipidemia before labeling familial hypercholesterolemia

Inherited disease should be pursued when the phenotype persists after reversible contributors are addressed.

When LDL-C is markedly elevated or response to statin therapy is unexpectedly poor, first evaluate for secondary dyslipidemia before assigning familial hypercholesterolemia. If secondary causes are excluded, assess for LDL receptor pathway disease using Dutch Lipid Clinic Network criteria, Simon Broome criteria, or ACC/AHA diagnostic criteria. [11]

Heterozygous familial hypercholesterolemia typically reflects a mutation affecting one allele, whereas homozygous familial hypercholesterolemia produces substantially more severe disease; LDL-C in heterozygous disease may be two to three times above normal. The distinction changes escalation because lomitapide and evinacumab are specifically considered for homozygous familial hypercholesterolemia. [11][12]

Use treatment response as a diagnostic and management discriminator. If a patient requires more than 25% additional LDL-C lowering despite maximally tolerated statin therapy, or has very high risk such as LDL-C greater than 190 mg/dL, PCSK9 inhibition can be initiated before ezetimibe rather than relying on ezetimibe alone, which typically lowers LDL-C by about 25%. [11]
- Apply formal familial hypercholesterolemia criteria after secondary dyslipidemia has been excluded. [11]
- Consider PCSK9 inhibitor therapy in heterozygous familial hypercholesterolemia aged 30 to 75 years when LDL-C remains at least 100 mg/dL despite maximally tolerated statin plus ezetimibe therapy. [13]
- Consider lomitapide or evinacumab for homozygous familial hypercholesterolemia. [12]

*Escalation clues in suspected familial hypercholesterolemia. [11][12][13]*

| Clinical situation | What it suggests | Therapeutic implication |
| --- | --- | --- |
| Secondary causes excluded with marked persistent LDL-C elevation | Familial hypercholesterolemia phenotype requiring formal diagnostic assessment. [11] | Use Dutch Lipid Clinic Network, Simon Broome, or ACC/AHA criteria. [11] |
| Need for >25% further LDL-C reduction on maximally tolerated statin | Ezetimibe alone may not provide adequate incremental lowering. [11] | Reasonably initiate a PCSK9 inhibitor before ezetimibe in very-high-risk patients. [11] |
| HeFH, age 30-75 years, LDL-C ≥100 mg/dL on statin plus ezetimibe | Persistent high LDL-C despite standard combination therapy. [13] | A PCSK9 inhibitor may be considered. [13] |
| HoFH | Extreme inherited LDL receptor pathway dysfunction. [11][12] | Consider lomitapide or evinacumab. [12] |

## Escalate LDL-C lowering according to residual risk and required incremental reduction

Use statin intensity and on-treatment LDL-C or non-HDL-C to determine the next agent.

For established ASCVD, maintain maximally tolerated statin therapy before adding nonstatins unless statin-attributed adverse effects preclude use. In very-high-risk ASCVD, add a PCSK9 monoclonal antibody when LDL-C remains at least 70 mg/dL or non-HDL-C remains at least 100 mg/dL despite ezetimibe and maximally tolerated statin therapy. [12]

For ASCVD not classified as very high risk in patients aged 75 years or younger, add ezetimibe when LDL-C remains at least 70 mg/dL on maximally tolerated statin therapy. If LDL-C remains at least 70 mg/dL despite the statin-ezetimibe combination, consider bempedoic acid; PCSK9 inhibition is appropriate when a larger additional LDL-C reduction is needed. [12]

In diabetes with statin-attributed adverse effects, ezetimibe, bempedoic acid, and/or a PCSK9 monoclonal antibody are recommended options to lower LDL-C and reduce ASCVD risk. Select among them based on needed LDL-C reduction, injection preference, cost, and ability to sustain adherence. [13]

Inclisiran is an option when less frequent injections are preferred, but cardiovascular outcome studies in ASCVD are ongoing. Do not equate LDL-C lowering with completed outcomes evidence when choosing between inclisiran and therapies with established cardiovascular benefit, including statins, ezetimibe, PCSK9 monoclonal antibodies, and icosapent ethyl. [12][13]
- Use LDL-C at least 70 mg/dL or non-HDL-C at least 100 mg/dL after statin plus ezetimibe as a threshold to add a PCSK9 monoclonal antibody in very-high-risk ASCVD. [12]
- Consider bempedoic acid when PCSK9 inhibitor cost is a major barrier. [12]
- Choose inclisiran when infrequent injection scheduling is a priority, while recognizing that ASCVD outcomes trials remain ongoing. [12][13]

*Practical nonstatin selection after maximally tolerated statin therapy. [11][12][13]*

| Clinical setting | Preferred next step | Escalation or tradeoff |
| --- | --- | --- |
| ASCVD, not very high risk, age ≤75 years, LDL-C ≥70 mg/dL | Add ezetimibe. [12] | Consider bempedoic acid if LDL-C remains ≥70 mg/dL after statin plus ezetimibe. [12] |
| Very-high-risk ASCVD, LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL despite statin plus ezetimibe | Add a PCSK9 monoclonal antibody. [12] | Consider bempedoic acid when PCSK9 inhibitor expense is prohibitive. [12] |
| Need >25% further LDL-C reduction or very-high-risk phenotype | Consider PCSK9 inhibitor before ezetimibe. [11] | Ezetimibe typically lowers LDL-C by about 25%, which may be insufficient. [11] |
| Diabetes with statin-attributed adverse effects | Use ezetimibe, bempedoic acid, and/or PCSK9 monoclonal antibody. [13] | Match therapy to required LDL-C lowering and feasibility of administration. [13] |
| Preference for less frequent injections | Consider inclisiran. [12] | ASCVD outcome studies are ongoing. [13] |

## Treat triglycerides above 500 mg/dL to reduce pancreatitis risk

Triglyceride-directed drugs have a different immediate goal than LDL-C–directed ASCVD prevention.

For persistent fasting triglycerides of 500 to 999 mg/dL in adults aged 20 to 39 years, emphasize a low-fat diet and consider fenofibrate or prescription omega-3 fatty acids to reduce pancreatitis risk. For those aged 40 to 75 years with 10-year ASCVD risk of at least 5%, diabetes, or ASCVD, initiate or intensify statin therapy in addition to a low-fat or very-low-fat diet and consideration of fenofibrate or prescription omega-3 fatty acids. [14]

Prescription omega-3 fatty acid products include EPA/DHA mixtures and purified EPA as icosapent ethyl. At 2 g twice daily, prescription omega-3 fatty acids lower triglycerides by approximately 30%. Low-dose omega-3 formulations have not reduced ASCVD events in primary or secondary prevention trials; cardiovascular event reduction has been shown in trials of EPA alone. [14]

Do not use triglyceride lowering alone as a substitute for LDL-C–directed prevention. In patients with ASCVD risk indications, statin therapy remains central, while fibrates and prescription omega-3 therapy are selected chiefly for severe triglyceride elevation and pancreatitis-risk reduction. [2][14]
- For adults aged 20 to 39 years with fasting triglycerides 500 to 999 mg/dL, consider fenofibrate or prescription omega-3 fatty acids after instituting a low-fat diet. [14]
- For adults aged 40 to 75 years with triglycerides 500 to 999 mg/dL plus ASCVD, diabetes, or 10-year ASCVD risk at least 5%, intensify statin therapy and consider fenofibrate or prescription omega-3 fatty acids. [14]
- Use prescription rather than low-dose over-the-counter omega-3 products when treating severe hypertriglyceridemia; 2 g twice daily lowers triglycerides by about 30%. [14]

*Management of persistent fasting triglycerides 500 to 999 mg/dL. [14]*

| Patient group | Diet and lipid therapy | Primary near-term objective |
| --- | --- | --- |
| Age 20-39 years | Low-fat diet; consider fenofibrate or prescription omega-3 fatty acids. [14] | Reduce pancreatitis risk. [14] |
| Age 40-75 years with ASCVD, diabetes, or 10-year ASCVD risk ≥5% | Initiate or intensify statin; use low-fat or very-low-fat diet; consider fenofibrate or prescription omega-3 fatty acids. [14] | Reduce pancreatitis risk while addressing ASCVD risk. [14] |
| Candidate for omega-3 therapy | Prescription omega-3 fatty acids at 2 g twice daily lower triglycerides by about 30%. [14] | Use purified EPA when ASCVD outcome benefit is the intended evidence-based consideration. [14] |

## Use Lp(a), ApoB, and coronary calcium when conventional risk assessment leaves uncertainty

Risk-enhancing biomarkers should change LDL-C intensity, not replace treatment of established disease.

Measure Lp(a) at least once in every adult to identify inherited elevation. Lp(a) at or above 125 nmol/L (50 mg/dL) is a risk-enhancing factor associated with about 1.4-fold higher ASCVD risk, and levels at or above 250 nmol/L (100 mg/dL) are associated with at least twofold higher estimated risk; these findings support intensified LDL-C lowering and more aggressive management of modifiable risk factors. [3]

An Lp(a) concentration above 180 mg/dL (430 nmol/L) identifies a very high inherited level with lifetime ASCVD risk comparable to heterozygous familial hypercholesterolemia. Because circulating Lp(a) is largely genetically determined and minimally modified by diet or environmental exposures, use the result for risk stratification and family-oriented clinical assessment rather than expecting lifestyle intervention to normalize it. [3][4]

Consider coronary artery calcium scoring to refine risk and guide LDL-C and non-HDL-C goals in men aged at least 40 years and women aged at least 45 years when primary-prevention treatment intensity remains uncertain. Interpret both absolute calcium burden and the age-, sex-, and race-standardized percentile because each adds prognostic information. [3]

Reassess the lipid panel after therapy changes to determine whether the patient has crossed the escalation threshold relevant to the treatment pathway, such as LDL-C 70 mg/dL or non-HDL-C 100 mg/dL in very-high-risk ASCVD. In patients with elevated triglycerides, diabetes, or low achieved LDL-C, repeat or obtain ApoB when discordance with LDL-C could change residual-risk assessment. [3][12]
- Treat Lp(a) ≥125 nmol/L (50 mg/dL) as a risk-enhancing factor that supports intensified LDL-C lowering. [3][4]
- Recognize Lp(a) ≥250 nmol/L (100 mg/dL) as associated with at least twofold higher estimated ASCVD risk. [3]
- Use coronary artery calcium in men ≥40 years and women ≥45 years when primary-prevention risk classification would change treatment intensity. [3]

*Risk-refining tests and actions. [3][4][12]*

| Test | Actionable result | What it changes |
| --- | --- | --- |
| Lp(a), once in adulthood | ≥125 nmol/L (50 mg/dL). [3] | Risk-enhancing finding supporting intensified LDL-C lowering and control of other risk factors. [3][4] |
| Lp(a), once in adulthood | ≥250 nmol/L (100 mg/dL). [3] | Associated with ≥2-fold higher estimated ASCVD risk. [3] |
| Lp(a), once in adulthood | >180 mg/dL (>430 nmol/L). [3] | Identifies inherited risk comparable to heterozygous familial hypercholesterolemia. [3] |
| ApoB | Elevated triglycerides, diabetes, or achieved LDL-C <70 mg/dL. [3] | Identifies residual particle-related risk that may be underestimated by standard LDL-C assessment. [3] |
| Coronary artery calcium | Men ≥40 years; women ≥45 years when risk remains uncertain. [3] | Absolute score and standardized percentile can reclassify risk and guide LDL-C and non-HDL-C goals. [3] |

## Common questions

### When should a PCSK9 inhibitor be used before ezetimibe?

Consider earlier PCSK9 inhibition when the patient needs more than 25% additional LDL-C lowering despite maximally tolerated statin therapy or has a very-high-risk phenotype such as LDL-C greater than 190 mg/dL; ezetimibe typically lowers LDL-C by about 25%. [11]

### Should low-dose omega-3 supplements be used for ASCVD prevention?

No. Low-dose omega-3 fatty acid trials have not shown primary or secondary ASCVD prevention benefit; cardiovascular outcome benefit has been demonstrated in trials of EPA alone. [14]

## References
1. Screening for Lipid Disorders in Children and Adolescents — jamanetwork.com — https://jamanetwork.com/JOURNALS/JAMA/FULLARTICLE/2542642
2. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016
3. 2026 Dyslipidemia Guideline-at-a-Glance - JACC — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2026.02.4872
4. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2024.02.031
5. Cholesterol Levels and Cardiovascular Outcomes Following Statin ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacadv.2025.101864
6. Executive summary of the Hellenic Atherosclerosis Society ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S266708952400004X
7. Lipid-lowering in diabetes: An update - ScienceDirect.com — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0021915023052346
8. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0033062023000130
9. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0021915020315975
10. [PDF] Advances in the treatment of dyslipidemia — www.ccjm.org — https://www.ccjm.org/content/ccjom/83/3/181.full.pdf
11. My adult patient’s hypercholesterolemia is not responding to statins—what’s next? | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/content/92/6/347
12. Stepwise Approach to Novel Lipid-Lowering Medications - American College of Cardiology — www.acc.org — https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2023/02/20/15/56/a-stepwise-approach
13. Lipid Manager - Mobile and Web Apps — tools.acc.org — https://tools.acc.org/ldl
14. ACC Consensus on ASCVD Risk Reduction in Hypertriglyceridemia — www.acc.org — https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2021/07/27/21/04/2021-acc-ecdp-hypertriglyceridemia
15. Importance and Management of Non–High-Density Lipoprotein ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacasi.2025.12.024
16. Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0163725823001717
17. Management of residual risk after statin therapy - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0021915015302483
18. Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0149291821002630

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.